Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Polycystic kidney disease: An early urea-selective urine-concentrating defect in ADPKD.

Bankir L, Bichet DG.

Nat Rev Nephrol. 2012 Jun 26;8(8):437-9. doi: 10.1038/nrneph.2012.139. No abstract available.

PMID:
22735763
2.

Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.

Zittema D, Boertien WE, van Beek AP, Dullaart RP, Franssen CF, de Jong PE, Meijer E, Gansevoort RT.

Clin J Am Soc Nephrol. 2012 Jun;7(6):906-13. doi: 10.2215/CJN.11311111.

3.

Urine and plasma osmolality in patients with autosomal dominant polycystic kidney disease: reliable indicators of vasopressin activity and disease prognosis?

Casteleijn NF, Zittema D, Bakker SJ, Boertien WE, Gaillard CA, Meijer E, Spithoven EM, Struck J, Gansevoort RT.

Am J Nephrol. 2015;41(3):248-56. doi: 10.1159/000382081.

4.

Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease.

Meijer E, Bakker SJ, van der Jagt EJ, Navis G, de Jong PE, Struck J, Gansevoort RT.

Clin J Am Soc Nephrol. 2011 Feb;6(2):361-8. doi: 10.2215/CJN.04560510.

5.

Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients.

Zittema D, van den Berg E, Meijer E, Boertien WE, Muller Kobold AC, Franssen CF, de Jong PE, Bakker SJ, Navis G, Gansevoort RT.

Clin J Am Soc Nephrol. 2014 Sep 5;9(9):1553-62. doi: 10.2215/CJN.08690813.

6.

Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation.

Ho TA, Godefroid N, Gruzon D, Haymann JP, Maréchal C, Wang X, Serra A, Pirson Y, Devuyst O.

Kidney Int. 2012 Nov;82(10):1121-9. doi: 10.1038/ki.2012.225.

7.

Bully renal cysts knock down urine-concentrating capacity in the early rounds.

Grantham JJ.

Clin J Am Soc Nephrol. 2012 Jun;7(6):875-7. doi: 10.2215/CJN.03720412. No abstract available.

8.

Evaluation of nephrolithiasis in autosomal dominant polycystic kidney disease patients.

Nishiura JL, Neves RF, Eloi SR, Cintra SM, Ajzen SA, Heilberg IP.

Clin J Am Soc Nephrol. 2009 Apr;4(4):838-44. doi: 10.2215/CJN.03100608.

9.

Evaluation of Th17 pathway in the diagnosis of autosomal dominant polycystic kidney disease.

Soleimani A, Adabavazeh R, Nikoueinejad H, Sharif MR, Faraji S, Otroshi Shahreza B, Akbari H, Einollahi B.

Iran J Kidney Dis. 2015 Mar;9(2):105-12.

10.

Exploring urinary biomarkers in autosomal dominant polycystic kidney disease.

Kawano H, Muto S, Ohmoto Y, Iwata F, Fujiki H, Mori T, Yan L, Horie S.

Clin Exp Nephrol. 2015 Oct;19(5):968-73. doi: 10.1007/s10157-014-1078-7.

PMID:
25543187
11.

Clinical and laboratory markers of autosomal dominant polycystic kidney disease (ADPKD) progression: an overview.

Corradi V, Gastaldon F, Virzì GM, Caprara C, Martino F, Ronco C.

Minerva Med. 2015 Feb;106(1):53-64. Review.

PMID:
25300895
12.

A comparative study of three kidney biomarker tests in autosomal-dominant polycystic kidney disease.

Casal JA, Hermida J, Lens XM, Tutor JC.

Kidney Int. 2005 Sep;68(3):948-54.

13.

Pravastatin Therapy and Biomarker Changes in Children and Young Adults with Autosomal Dominant Polycystic Kidney Disease.

Klawitter J, McFann K, Pennington AT, Wang W, Klawitter J, Christians U, Schrier RW, Gitomer B, Cadnapaphornchai MA.

Clin J Am Soc Nephrol. 2015 Sep 4;10(9):1534-41. doi: 10.2215/CJN.11331114.

14.

Copeptin levels and kidney function in ADPKD: case-control study.

Corradi V, Martino F, Gastaldon F, Scalzotto E, Caprara C, Fortunato A, Pinaffo G, Marchetti C, Fabbi F, Giavarina D, Ferrari F, Rosner MH, Ronco C.

Clin Nephrol. 2016 Sep;86(9):147-53. doi: 10.5414/CN108894.

PMID:
27487355
15.

Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease.

Zheng D, Wolfe M, Cowley BD Jr, Wallace DP, Yamaguchi T, Grantham JJ.

J Am Soc Nephrol. 2003 Oct;14(10):2588-95.

16.

Evaluation of urine biomarkers of kidney injury in polycystic kidney disease.

Parikh CR, Dahl NK, Chapman AB, Bost JE, Edelstein CL, Comer DM, Zeltner R, Tian X, Grantham JJ, Somlo S.

Kidney Int. 2012 Apr;81(8):784-90. doi: 10.1038/ki.2011.465.

17.

Urinary biomarkers at early ADPKD disease stage.

Petzold K, Poster D, Krauer F, Spanaus K, Andreisek G, Nguyen-Kim TD, Pavik I, Ho TA, Serra AL, Rotar L.

PLoS One. 2015 Apr 13;10(4):e0123555. doi: 10.1371/journal.pone.0123555.

18.

Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort.

Boertien WE, Meijer E, Li J, Bost JE, Struck J, Flessner MF, Gansevoort RT, Torres VE; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease CRISP..

Am J Kidney Dis. 2013 Mar;61(3):420-9. doi: 10.1053/j.ajkd.2012.08.038.

19.

Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis.

Meijer E, Boertien WE, Nauta FL, Bakker SJ, van Oeveren W, Rook M, van der Jagt EJ, van Goor H, Peters DJ, Navis G, de Jong PE, Gansevoort RT.

Am J Kidney Dis. 2010 Nov;56(5):883-95. doi: 10.1053/j.ajkd.2010.06.023.

PMID:
20888104
20.

Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).

Nakajima A, Lu Y, Kawano H, Horie S, Muto S.

Clin Exp Nephrol. 2015 Dec;19(6):1199-205. doi: 10.1007/s10157-015-1101-7.

PMID:
25715868

Supplemental Content

Support Center